Suvajit Sen, Ph.D. PMP ISMPP CMPP

Experience

• 

  UCLA

  Jan 2007 - Jan 2020

  http://www.cancer.ucla.edu/research/find-become-a-member/member-directory?id=712• Published over 27 original articles (12 as a first author including 9 as a corresponding author) in the area of heme protein mutations, breast & ovarian cancer, cardiovascular and reproductive biology• Authored book chapters in the area of Nitric Oxide mediated signals and Chemosensitivity in Cancer• Authored invited review articles on endothelial biology • Served as an invited speaker at international conferences on gynecological cancers • Served as an invited reviewer for more than 20 peer-reviewed scientific manuscripts, such as Oncotarget, Current Topics in Medicinal Chemistry and PLOS ONE • Presented scientific findings and business pitches to the national and international scientific community • Trained and mentored research associates / assistants• Taught undergraduate classes in biomedical sciences at UCLA • Performed signaling and metabolic studies utilizing xenograft models of cancer • Identified targets and biomarkers related to the action of hydrogen sulfide in tumor biology• Preclinical identified of cystathionine as an oncometabolite (biomarker for drug resistance in breast cancer)• Preclinical identification of hydrogen sulfide as a modulator of innate immunity in the tumor microenvironment of breast cancer• Identified the role of hydrogen sulfide and nitric oxide and other small diffusible metabolites in solid tumors• Investigated a novel role of gamma amino butyric acid (as a biomarker), in cardiovascular systems and rare conditions such as preeclampsia • Prepared extensive protocols for clinical studies and translational investigations approved by the Internal Review Board at the University of Californian at Los Angeles Show less Assistant Researcher I (07/2009 – 06/2012)Conducted research to investigate mechanistic pathways involved in nitric oxide and reactive oxygen species mediated proliferation of ovarian breast cancer. Identified mechanistic pathways leading to apoptosis in endothelial cells as evidenced by peer-reviewed publications.• Worked with breast tumor tissues isolated from cancer patients at the core pathological laboratory at UCLA. • Developed collaborative relationships with leading experts and KOLs in the field of Nitric Oxide and Reactive Oxygen Species. • Compiled, analyzed, published, and presented research data.• Trained and mentored research associates and graduate students. Show less Initiated, planned, and conducted research projects to investigate nitric oxide dependent pathways in human breast cancer models. • Developed strategies for breast and ovarian cancer treatments based on the differential status of reactive oxygen species sampled by tumor cells.• Explored pathways involved in the malfunctioning of the cardio vascular system using fresh endothelial cells from umbilical cords. • Built productive collaborations with clinical scientists. • Mentored undergraduate students, graduate students and clinical fellows.• Published research in peer-reviewed journals. Show less

  • Assistant Professor, Dept of Obstetrics and Gynecology, Member JCCC Signal Transduction/Therapy

    Jan 2012 - Jan 2020

  • Assistant Researcher

    Jan 2009 - Jan 2012

  • Postdoctoral Fellow

    Jan 2007 - Jan 2009
• 

  CareDx, Inc.

  Jan 2016 - Jan 2017

  Senior Clinical Scientist - Consultant

  • Oversaw compilation of scientific manuscripts, analyzed logic and data content and manages submission deadlines in the area of noninvasive markers for the assessment of allograft rejections • Identified journals that were appropriate for the publication of specific studies • Participated in the timely analysis and submission of data in clinically relevant peer reviewed journals, such as Circulation Heart Failure and Clinical Transplantation• Initiated meetings with KOLs, MSLs and other clinical scientists to analyze clinical data and assess the overall suitability for publication • Interacted with in house statisticians and KOLs to achieve proper interpretation of clinical data • As a consultant clinical scientist, successfully managed the submission of three and initiated the submission of four clinical manuscripts within a span of 4 months Show less

• 

  Exelixis

  Jan 2017 - Jan 2022

  • Development of publication planning and strategies for Phase III & Phase 1b/II oncology studies; clinical, translational and biomarker evaluations• Participation in advisory board meetings to gather inputs regarding trial efficacy and safety • Interpretation and publication of clinical data on targeted therapies and immune oncology• Cross-functional collaborations with clinical, translational, bio-stats and preclinical/discovery development to interpret data and content-development for publications & presentations• Development of scientific training decks, SOPs and compliant materials• Management of KOL engagement to strategize data interpretation and dissemination • Active management of multiple CROs Operating publication management softwares such as DataVision • Managing direct reports Show less • Provided clinical and scientific input for developing clinical-scientific publications and presentations • Engaged with cross functional departments such as clinical science, bio stats, safety and compliance towards the development and review of company sponsored trials and investigator initiated clinical studies • Interacted with KOLs for their recruitment and involvement in publication efforts • Facilitated overall publication planning considering current indication landscapes and management of publications for early phase and phase III trials • Trained MSLs on mechanism of actions of various study drugs and marketed drugs Show less

  • Director, Medical Affairs / Medical Communications

    Jan 2020 - Jan 2022

  • Associate Director, Medical Affairs / Medical Communications

    Jan 2017 - Jan 2020
• 

  Adicet Bio, Inc

  May 2022 - Oct 2022

  Sr. Director, Medical Affairs

  ● Actively engaged in ad board organization and related activities● Analyzing the competitive and treatment landscapes to inform study design● Identifying indications for novel CART cell therapy products in the Hematology/Oncology space● Understanding payer behaviors and reimbursement schemes for treatment options ● Developing protocol synopsis for late phase clinical trial in advanced diffuse B-cell lymphoma● Involved in KOL engagement and scientific exchanges

• 

  Kartos Therapeutics, Inc.

  Oct 2022 - now

  Executive Director; Medical Affairs (Medical Communications)

  ● Medical and Scientific communications; publication planning and execution (strategy and tactics) ● Designing and organizing internal medical education in alignment with company’s strategic and educational interests keeping an eye towards the competitive and treatment landscape● Chairing the Grant Review Committee to triage proposals for investigator sponsored trials ● Assessing scientific messaging for various Congress related activities

• 

  Vaniam Group

  Sept 2023 - now

  Scientific Communications-Lead